http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108339120-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
| filingDate | 2017-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108339120-B |
| titleOfInvention | Application of protein kinase A activator in preparing medicine for treating diseases related to platelet quantity reduction |
| abstract | The invention discloses an application of a protein kinase A activator in preparing a medicament for treating diseases related to platelet number reduction. The invention researches the effect of protein kinase A in the process of regulating and controlling the platelet apoptosis for the first time through experiments, finds that the activity of protein kinase A in platelets in thrombocytopenic patients represented by idiopathic thrombocytopenic purpura, bacterial infection and diabetes is reduced, and researches prove that the protein kinase A regulates and controls the platelet apoptosis by regulating and controlling the phosphorylation of serine at a BAD 155 site, and the activation of the activity of the protein kinase A can inhibit the occurrence of endogenous platelet apoptosis. The protein kinase A activator can inhibit the occurrence of platelet apoptosis in vitro and improve the number of circulating platelets in vivo of experimental animals, and the PKA activator can be used for the clinical treatment process of thrombocytopenia by inhibiting platelet apoptosis, has the potential of developing novel platelet protection medicines, and has scientific research and economic values. |
| priorityDate | 2017-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 268.